Ultrasensitive Alzheimer’s disease biomarker detection with nanopillar photonic crystal biosensors
Optica · 20.10.2025 · 12 (10) · 1587
DOI: 10.1364/optica.566672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Optica, online erschienen am 02.10.2025. Verfasst von Guilherme S Arruda und 8 weiteren Autor:innen. Beteiligte Einrichtung: São Carlos School of Engineering, Department of Electrical and Computer Engineering, University of São Paulo, São Carlos, SP 13566-590, Brazil. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Engineering and Physical Sciences Research Council.
Themen: Demenz
Abstract (Originalsprache)
The recent development of drugs able to mitigate neurodegenerative diseases has created an urgent need for biomarker tests that can be readily used by practitioners. Although biomarker detection directly in patients’ blood is now possible, low-cost point-of-care tests remain a challenge because relevant biomarkers, especially amyloid- β ( A β ) peptides, are small, they occur at very low concentrations, and detecting a single marker is insufficient. Here, we demonstrate a photonic resonant sensor able to detect 0.2 pg/ml of A β 42 and A β 40 in 1% human blood serum, equivalent to 20 pg/ml in undiluted serum, which is the clinically required level. This high performance is achieved by combining gold nanoparticle amplification with a dielectric nanopillar photonic crystal structure in a dimer configuration, while also employing an immunoassay approach for high selectivity and specificity. The design combines high resonance Q-factor, amplitude, and sensitivity, ideally suited for sensing. We also show the detection of A β 42 and A β 40 peptides in the same channel, which is highly relevant for assessing disease progress and opens a route toward multiplexing. Together with the handheld operation we have demonstrated previously, these photonic innovations make a major contribution to the ability to detect and monitor the progression of neurodegenerative diseases such as Alzheimer’s.
Autor:innen und Institutionen
- São Carlos School of Engineering, Department of Electrical and Computer Engineering, University of São Paulo, São Carlos, SP 13566-590, Brazil.
- School of Physics, Engineering and Technology, University of York, York YO10 5DD, UK.
- Department of Pure and Applied Chemistry, University of Strathclyde, Technology and Innovation Centre, Glasgow G1 1RD, UK.
- York Biomedical Research Institute, University of York, York YO10 5DD, UK.
ORCID-Profile: Guilherme S Arruda, Katie Morris, Augusto Martins, Yue Wang, Emiliano R Martins
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Engineering and Physical Sciences Research Council
- Wellcome Trust
- Alzheimer’s Research UK
- Alzheimer’s Research UK Yorkshire Network
- Alzheimer’s Society
Zitieren
APA
Arruda, G. S., Morris, K., Martins, A., Wang, Y., Sloan-Dennison, S., Graham, D., Quinn, S. D., Martins, E. R., & Krauss, T. F. (2025). Ultrasensitive Alzheimer’s disease biomarker detection with nanopillar photonic crystal biosensors. Optica, 12(10), 1587. https://doi.org/10.1364/optica.566672
Vancouver
Arruda GS, Morris K, Martins A, Wang Y, Sloan-Dennison S, Graham D, et al. Ultrasensitive Alzheimer’s disease biomarker detection with nanopillar photonic crystal biosensors. Optica. 2025;12(10):1587. doi:10.1364/optica.566672
BibTeX
@article{Arruda2025,
author = {Arruda, Guilherme S and Morris, Katie and Martins, Augusto and Wang, Yue and Sloan-Dennison, Sian and Graham, Duncan and Quinn, Steven D and Martins, Emiliano R and Krauss, Thomas F},
title = {Ultrasensitive Alzheimer’s disease biomarker detection with nanopillar photonic crystal biosensors},
journal = {Optica},
year = {2025},
volume = {12},
number = {10},
pages = {1587},
doi = {10.1364/optica.566672}
}
EUVIMED